Safety and tolerability change from baseline in laboratory assessments Part A: Approximately 58 days and Part B: Approximately 38 days. [clinicaltrials_resource:23ed9d322b4d9d11829abaa0316ae278]

Safety and tolerability change from baseline in laboratory assessments Part A: Approximately 58 days and Part B: Approximately 38 days. [clinicaltrials_resource:23ed9d322b4d9d11829abaa0316ae278]

Hematology, Clinical Chemistry, Urinalysis
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:23ed9d322b4d9d11829abaa0316ae278

Safety and tolerability change from baseline in laboratory assessments Part A: Approximately 58 days and Part B: Approximately 38 days. [clinicaltrials_resource:23ed9d322b4d9d11829abaa0316ae278]

Hematology, Clinical Chemistry, Urinalysis
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:23ed9d322b4d9d11829abaa0316ae278
Bio2RDF identifier
23ed9d322b4d9d11829abaa0316ae278
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:23ed9d322b4d9d11829abaa0316ae278
measure [clinicaltrials_vocabulary:measure]
Safety and tolerability change from baseline in laboratory assessments
time frame [clinicaltrials_vocabulary:time-frame]
Part A: Approximately 58 days and Part B: Approximately 38 days.
description
Hematology, Clinical Chemistry, Urinalysis
identifier
clinicaltrials_resource:23ed9d322b4d9d11829abaa0316ae278
title
Safety and tolerability change ...... Part B: Approximately 38 days.
@en
inDataset
type
label
Safety and tolerability change ...... d9d322b4d9d11829abaa0316ae278]
@en